Please review Indications and Usage before proceeding.
INDICATIONS AND USAGE
TEFLARO® (ceftaroline fosamil)
is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age and older)
for the treatment of
acute bacterial skin and skin structure infections (ABSSSI)
caused by susceptible isolates of the
following Gram-positive and Gram-negative microorganisms:
Staphylococcus aureus (including methicillin-susceptible
and -resistant isolates),
Streptococcus pyogenes,
Streptococcus agalactiae, Escherichia coli,
Klebsiella pneumoniae,
and
Klebsiella oxytoca.
TEFLARO is also indicated in adult and pediatric patients 2 months of age and older for the treatment of
community-acquired bacterial pneumonia (CABP)
caused by susceptible isolates of the following Gram-positive
and Gram-negative microorganisms: Streptococcus pneumoniae
(including cases with concurrent bacteremia),
Staphylococcus aureus
(methicillin-susceptible isolates only),
Haemophilus
influenzae, Klebsiella pneumoniae, Klebsiella oxytoca,
and
Escherichia coli.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of TEFLARO
and other antibacterial drugs, TEFLARO should be used to treat only ABSSSI or CABP that are proven
or strongly suspected to be caused by susceptible bacteria. Appropriate specimens for microbiological
examination should be obtained in order to isolate and identify the causative pathogens and to determine
their susceptibility to ceftaroline. When culture and susceptibility information are available, they
should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local
epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
By continuing, you are confirming that you have read the Indications and Usage.